Organon & Co.
Organon & Co. is a U.S.-based global healthcare company focused on women’s health and general medicines, including biosimilars. Its portfolio spans more than 70 products sold in over 140 countries and territories through wholesalers, retailers, hospitals, government agencies, and managed healthcare organizations.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaPrescription products used in contraception and other women’s health needs.
Established branded medicines used across primary and specialty care.
Biologic follow-on medicines commercialized through external partners.
Tuotteet
Raportoitu · osuus liikevaihdosta- Nexplanon Implanon NXT14,8 %
- Zetia5,5 %
- Other Sundry Established Brands5,4 %
- Atozet5,2 %
- Other Non Opiod Pain Bone and Dermatology4,8 %
- Muut64,2 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Organon sells primarily to healthcare intermediaries rather than directly to end consumers, including wholesalers, retailers, hospitals, government agencies, and managed healthcare providers. Demand is driven by physicians, patients, and payors that use or reimburse prescription medicines, with women’s health being a core end-market.
Buy in bulk for downstream distribution and are central to U.S. and international channel access.
Health plans, PBMs, and HMOs that shape formulary access, rebates, and patient uptake.
Purchase medicines used in institutional care settings and specialty treatment pathways.
Public-sector buyers that procure medicines for national or regional health programs.
Dispense branded prescription products to patients through prescription fulfillment.
Strategia
Organon’s strategy centers on women’s health, maintaining a broad portfolio of established medicines, and expanding access across global markets. The company also relies on external alliances and commercialization partnerships, especially for biosimilars, while using its global sales and access capabilities to support product uptake.
Women’s health is the company’s defining therapeutic focus and a major source of brand recognition.
Partnering reduces the need to build all development and manufacturing capabilities internally.
Prescription medicines depend on reimbursement, wholesaler stocking, and formulary access.
Maantiede
Q1/2026Organon operates globally, with products sold in more than 140 countries and territories. Manufacturing is concentrated in six facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom, which supports a geographically diversified supply chain and regional market access.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Organon faces patent, regulatory, manufacturing, and supply-chain risks typical of branded pharmaceuticals, with added exposure from biosimilars and external partners. Its revenue is also sensitive to channel inventory behavior, pricing/rebate dynamics, and the ability to maintain access across diverse healthcare systems.
- Patent invalidation or circumventionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Branded pharmaceutical sales depend on enforceable intellectual property protection.
Kohdistuu: Key products with patent protection
- Biosimilar regulatory and execution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biosimilars require complex development, approval, and partner execution.
Kohdistuu: Biosimilar portfolio
- Manufacturing and supply disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on a limited set of manufacturing sites and third-party inputs.
Kohdistuu: Global supply chain and six manufacturing facilities
- Regulatory and compliance enforcementVaikutus: KorkeaTodennäköisyys: Kohtalainen
Pharmaceutical promotion, pricing, and product approvals are heavily regulated.
Kohdistuu: U.S. FDA and international markets
- Channel inventory and rebate volatilityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Wholesaler stocking, chargebacks, and rebates can materially affect reported revenue.
Kohdistuu: U.S. and managed-care channels
Kirjanpito
Harkinnanvaraiset erätDiscounts, rebates, chargebacks, and returns materially reduce reported sales.
Vaikutus: Affects net revenue and quarterly comparability
Management estimates U.S. rebates and chargebacks using channel and utilization data.
Vaikutus: Can create accrual adjustments if assumptions change
Factoring is used in certain countries to manage cash conversion.
Vaikutus: Affects operating cash flow and working capital
Acquisition-related earnouts can generate periodic expense as estimates change.
Vaikutus: Impacts other expense and acquisition accounting
Product rights and acquired intangibles depend on future sales and patent life.
Vaikutus: Could lead to non-cash impairment charges
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Organogenesis Holdings Inc.
ORGO · Pharmaceutical Preparations
Regeneron Pharmaceuticals, Inc
REGN · Pharmaceutical Preparations
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases.
Repligen Corporation
RGEN · Biological Products, (No Diagnostic Substances)
Progyny, Inc.
PGNY · Services-Misc Health & Allied Services, NEC
Revvity, Inc
RVTY · Laboratory Analytical Instruments
Revvity is a U.S.-based health science company that develops instruments, software, reagents, and services used across research, screening, diagnostics, and reproductive health workflows.
Escalon Medical Corp
ESMC · Electromedical & Electrotherapeutic Apparatus
Päivitetty: 24.9.2026